News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
288,631 Results
Type
Article (15152)
Company Profile (299)
Press Release (273174)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (81641)
Career Advice (174)
Deals (13691)
Drug Delivery (39)
Drug Development (51097)
Employer Resources (32)
FDA (6389)
Job Trends (5296)
News (148365)
Policy (10478)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (939)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (22148)
ALS (126)
Alzheimer's disease (1051)
Antibody-drug conjugate (ADC) (241)
Approvals (6585)
Artificial intelligence (261)
Autoimmune disease (110)
Automation (9)
Bankruptcy (106)
Best Places to Work (4686)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (346)
Cancer (3163)
Cardiovascular disease (243)
Career advice (158)
Career pathing (7)
CAR-T (218)
CDC (5)
Cell therapy (565)
Cervical cancer (15)
Clinical research (44008)
Collaboration (1154)
Company closure (2)
Compensation (591)
Complete response letters (41)
COVID-19 (1124)
CRISPR (86)
C-suite (554)
Cystic fibrosis (112)
Data (4356)
Denatured (15)
Depression (92)
Diabetes (260)
Diagnostics (1476)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (189)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (32849)
Editorial (25)
Employer branding (4)
Employer resources (31)
Events (52259)
Executive appointments (622)
FDA (8187)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (986)
Gene editing (182)
Generative AI (21)
Gene therapy (487)
GLP-1 (508)
Government (1180)
Grass and pollen (3)
Guidances (185)
Healthcare (6816)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (40)
Indications (67)
Infectious disease (1234)
Inflammatory bowel disease (161)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (168)
Interviews (20)
IPO (7561)
IRA (12)
Job creations (873)
Job search strategy (136)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (10)
Legal (1436)
Liver cancer (41)
Longevity (11)
Lung cancer (423)
Lymphoma (248)
Machine learning (24)
Management (8)
Manufacturing (375)
MASH (130)
Medical device (2991)
Medtech (3003)
Mergers & acquisitions (6759)
Metabolic disorders (733)
Multiple sclerosis (103)
NASH (13)
Neurodegenerative disease (232)
Neuropsychiatric disorders (71)
Neuroscience (1979)
Neurotech (1)
NextGen: Class of 2026 (2062)
Non-profit (898)
Now hiring (30)
Obesity (332)
Opinion (128)
Ovarian cancer (132)
Pain (105)
Pancreatic cancer (162)
Parkinson's disease (233)
Partnered (12)
Patents (302)
Patient recruitment (332)
Peanut (43)
People (26902)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15529)
Phase 2 (20398)
Phase 3 (12982)
Pipeline (3291)
Policy (91)
Postmarket research (881)
Preclinical (6558)
Press Release (31)
Prostate cancer (156)
Psychedelics (51)
Radiopharmaceuticals (240)
Rare diseases (649)
Real estate (1494)
Recruiting (13)
Regulatory (10268)
Reports (19)
Research institute (983)
Resumes & cover letters (20)
Rett syndrome (24)
RNA editing (21)
RSV (20)
Schizophrenia (123)
Series A (182)
Series B (137)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (17)
Startups (2015)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (340)
Venture capital (69)
Weight loss (176)
Women's health (25)
Worklife (2)
Date
Today (6)
Last 7 days (351)
Last 30 days (1317)
Last 365 days (18069)
2026 (1680)
2025 (18333)
2024 (20842)
2023 (22737)
2022 (27270)
2021 (28274)
2020 (23874)
2019 (16713)
2018 (12118)
2017 (14123)
2016 (12206)
2015 (14761)
2014 (10689)
2013 (7783)
2012 (7883)
2011 (7973)
2010 (7737)
Location
Africa (166)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18805)
Australia (3160)
California (7161)
Canada (1851)
China (774)
Colorado (256)
Connecticut (254)
Delaware (235)
Europe (40360)
Florida (906)
Georgia (212)
Hawaii (2)
Idaho (17)
Illinois (399)
India (35)
Indiana (162)
Iowa (8)
Japan (222)
Kansas (81)
Kentucky (9)
Louisiana (8)
Maine (11)
Maryland (750)
Massachusetts (5596)
Michigan (116)
Minnesota (271)
Mississippi (3)
Missouri (34)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (28)
New Jersey (1696)
New Mexico (13)
New York (1781)
North Carolina (839)
North Dakota (6)
Northern California (3511)
Ohio (181)
Oklahoma (11)
Oregon (24)
Pennsylvania (1304)
Puerto Rico (9)
Rhode Island (26)
South America (231)
South Carolina (9)
Southern California (2852)
Tennessee (40)
Texas (924)
United States (23653)
Utah (97)
Virginia (137)
Washington D.C. (38)
Washington State (604)
West Virginia (1)
Wisconsin (45)
288,631 Results for "confo therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia
December 18, 2025
·
4 min read
Press Releases
Confo Therapeutics Awarded VLAIO Grant for Development of Ultra-Long-Acting Antibody-Based GPCR Therapeutics in Endocrine and Metabolic Conditions
October 8, 2025
·
2 min read
Confo Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development in Endocrine and Metabolic Diseases
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors, announced that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship.
March 28, 2024
·
2 min read
Business
Confo Therapeutics Appoints Stephen Dowd as Chief Business Officer
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors, announced the appointment of Stephen Dowd, PhD, MBA, to its executive team as Chief Business Officer.
September 12, 2023
·
2 min read
Business
Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors.
August 29, 2023
·
3 min read
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that it has entered into a research collaboration with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.
June 15, 2023
·
2 min read
Job Trends
Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds.
March 2, 2023
·
3 min read
Press Releases
Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety
October 1, 2024
·
4 min read
Business
Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases
Confo Therapeutics announced that it has entered a collaboration agreement with Daiichi Sankyo for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.
March 30, 2023
·
2 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
1 of 28,864
Next
